RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MASI G
Collezione ASL Biella

Items : 7

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Casadei-Gardini A; Rimassa L; Antonuzzo L; Vivaldi C; Stefano C; Foti S; Rizzato MD; De Braud F; Aldrighetti L; Ratti F; Zanuso V; De Rosa A; Niger M; Rossari F; Fornaro L; Satolli MA; Brandi G; Garattini SK; Brunetti O; Pirrone C; Leone F; Diana A; Pretta A; Toma I; Landriscina M; Lorenzo A; Gusmaroli E; Bergamo F; Balsano R; et alii...

Prognostic and predictive role of FGFR2 and IDH1 targetable alterations in advanced biliary tract cancer (aBTC): Data from the Italian ANITA dataset in Annals of Oncology

2024
ASL Biella

Genovesi V; Rimini M; Pressiani T; Soldà C; Nichetti F; Salvatore L; Antonuzzo L; Silvestro L; Diana A; Leone F; Foti S; Balsano R; Piva VM; Pircher CC; Camera S; Masi G; Rimassa L; De Grandis MC; Gardini AC; Fornaro L;

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. in Cancers / Cancers (Basel). 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900.

2023
ASL Biella
AO Cuneo

Masi G; Aprile G; Fornaro L; De Manzoni G; Basile D; Bencivenga M; Vasile E; Leone F; Montagnani F; Puzzoni M; Scartozzi M; Ribero D; Vivaldi C; Fanotto V; Salani F;

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO in Annals of Oncology

2023
ASL Biella

Conca V; Antoniotti C; Bergamo F; Pietrantonio F; Rossini D; Scartozzi M; Perissinotto E; Leone A; Pusceddu V; Borelli B; Cavanna L; Latiano T; Santini D; Masi G; Salvatore L; Frassineti G; Leone F; Tamberi S; Boni L; Cremolini C;

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. in Journal of chemotherapy (Florence, Italy) / J Chemother. 2022 Dec;34(8):543-549. doi: 10.1080/1120009X.2022.2036557. Epub 2022 Feb 14.

2022
ASL Biella
AOU Città della Salute di Torino
AO Ordine Mauriziano

Aldrighetti L; Sperti E; Burgio V; Ratti F; Cucchetti A; Cascinu S; Faloppi L; Pellino A; Salani F; Scartozzi M; Vivaldi C; Satolli MA; Fenocchio E; Aprile G; Frega G; Aglietta M; Santini D; Palloni A; Filippi R; Masi G; Galizia E; Silvestris N; Montagnani F; Lonardi S; Lai E; Fornaro L; Pella N; Leone F; Brandi G; et alii...

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study in Journal of Clinical Oncology

2016
ASL Biella

Marmorino F; Cremolini C; Loupakis F; Barbara C; Dargenio F; Miraglio E; Masi G; Salvatore L; Marcucci L; Antonuzzo L; Chiara S; Banzi C; Schirripa M; Amoroso D; Bonetti A; Martignetti A; Paris M; Boni L; Tomcikova D; Falcone A;